+

DK1162999T3 - Vaccine imod Streptococcus pneumoniae - Google Patents

Vaccine imod Streptococcus pneumoniae

Info

Publication number
DK1162999T3
DK1162999T3 DK00916983T DK00916983T DK1162999T3 DK 1162999 T3 DK1162999 T3 DK 1162999T3 DK 00916983 T DK00916983 T DK 00916983T DK 00916983 T DK00916983 T DK 00916983T DK 1162999 T3 DK1162999 T3 DK 1162999T3
Authority
DK
Denmark
Prior art keywords
streptococcus pneumoniae
vaccine against
against streptococcus
vaccine
pneumoniae
Prior art date
Application number
DK00916983T
Other languages
Danish (da)
English (en)
Inventor
Carine Capiau
Marguerite Deschamps
Pierre Michel Desmons
Craig A J Laferriere
Jan Poolman
Jean-Paul Prieels
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1162999T3 publication Critical patent/DK1162999T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00916983T 1999-03-19 2000-03-17 Vaccine imod Streptococcus pneumoniae DK1162999T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002467 WO2000056359A2 (fr) 1999-03-19 2000-03-17 Vaccin

Publications (1)

Publication Number Publication Date
DK1162999T3 true DK1162999T3 (da) 2007-03-26

Family

ID=27451884

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00916983T DK1162999T3 (da) 1999-03-19 2000-03-17 Vaccine imod Streptococcus pneumoniae
DK00912626T DK1163000T3 (da) 1999-03-19 2000-03-17 Vacciner imod antigener fra bakterier

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00912626T DK1163000T3 (da) 1999-03-19 2000-03-17 Vacciner imod antigener fra bakterier

Country Status (32)

Country Link
US (8) US20030147922A1 (fr)
EP (6) EP1163000B1 (fr)
JP (4) JP2002539273A (fr)
KR (3) KR20020000785A (fr)
CN (3) CN1192798C (fr)
AR (3) AR022963A1 (fr)
AT (3) ATE346608T1 (fr)
AU (3) AU750762B2 (fr)
BE (1) BE1025464I2 (fr)
BR (4) BR0009154A (fr)
CA (3) CA2366314C (fr)
CY (3) CY1107561T1 (fr)
CZ (3) CZ301445B6 (fr)
DE (4) DE60038166T2 (fr)
DK (2) DK1162999T3 (fr)
ES (3) ES2300255T3 (fr)
FR (1) FR10C0008I2 (fr)
HK (3) HK1043730A1 (fr)
HU (4) HU229968B1 (fr)
IL (5) IL145044A0 (fr)
LU (1) LU91652I2 (fr)
MX (1) MXPA01009452A (fr)
MY (2) MY125387A (fr)
NL (1) NL300415I1 (fr)
NO (4) NO330532B1 (fr)
NZ (3) NZ513840A (fr)
PL (3) PL204890B1 (fr)
PT (2) PT1163000E (fr)
SI (2) SI1163000T1 (fr)
TR (3) TR200102739T2 (fr)
TW (3) TWI235064B (fr)
WO (3) WO2000056360A2 (fr)

Families Citing this family (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
EP0909323B1 (fr) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bacterioferritine de helicobacter pilori
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
SI1163000T1 (sl) * 1999-03-19 2008-06-30 Glaxosmithkline Biolog Sa Vakcina proti antigenom iz bakterij
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
EP2957300B1 (fr) 2001-01-23 2021-07-14 Sanofi Pasteur Inc. Vaccin conjugué de protéine et de polysaccharide pour méningococcie polyvalente
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2469620A1 (fr) 2001-12-12 2003-06-19 Chiron Srl. Immunisation contre chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US20060147466A1 (en) * 2002-05-14 2006-07-06 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US7485710B2 (en) * 2002-10-15 2009-02-03 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
AR041881A1 (es) 2002-11-01 2005-06-01 Glaxosmithkline Biolog Sa Procedimiento de secado para la obtencion de un liquido altamente viscoso que conserva la antigenicidad o actividad de una agente activo y vacuna obtenida a partir de el
PT1565478T (pt) 2002-11-12 2017-11-14 The Brigham And Women`S Hospital Inc Vacina de polissacáridos para infeções estafilocócicas
AU2003288660A1 (en) 2002-11-15 2004-06-15 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
US8034378B2 (en) 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
CN101926988B (zh) * 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
DK1601689T3 (da) * 2003-03-13 2008-03-25 Glaxosmithkline Biolog Sa Oprensningsfremgangsmåde for bakterielt cytolysin
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
AU2004277758A1 (en) * 2003-10-02 2005-04-14 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
JP5718545B2 (ja) 2004-04-30 2015-05-13 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 髄膜炎菌結合体ワクチン接種
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CA2571421A1 (fr) 2004-06-24 2006-01-05 Nicholas Valiante Composes utilises pour l'immunopotentialisation
EP1768662A2 (fr) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
WO2006078318A2 (fr) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Compositions immunogenes pour bacteries a gram positif telles que streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP1855715B1 (fr) 2005-01-27 2013-03-13 Children's Hospital & Research Center at Oakland Vaccins vesiculaires a base de gna1870 conferant une protection a large spectre contre les maladies provoquees par neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
CN101180312A (zh) 2005-02-18 2008-05-14 诺华疫苗和诊断公司 来自尿路病原性大肠杆菌的免疫原
NZ597685A (en) 2005-02-18 2013-12-20 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
RS52249B (en) 2005-04-08 2012-10-31 Wyeth Llc MULTIVALENT COMPOSITION WITH CONJUGATE OF PNEUMOCOCOCH POLISACCHARIDE AND PROTEIN
WO2006113528A2 (fr) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Procede pour exprimer un antigene de surface de virus de l'hepatite b afin de preparer un vaccin
PT1896061T (pt) 2005-06-27 2019-08-01 Glaxosmithkline Biologicals Sa Composição imunogénica
EP2308504A3 (fr) 2005-09-01 2011-11-30 Novartis Vaccines and Diagnostics GmbH Vaccins multiples comprenant le sérogroupe C de Neisseria meningitidis
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2634887C (fr) * 2005-12-22 2016-01-19 Glaxosmithkline Biologicals Sa Vaccins pneumococciques a base de conjugues de saccharides capsulaires
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2636566C (fr) * 2006-01-17 2018-03-13 Arne Forsgren Nouvelle proteine de haemophilus influenzae a surface exposee (proteine; pe)
CN101024079B (zh) * 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
EP3006041B1 (fr) * 2006-03-17 2017-11-29 The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services Procédé de préparation de conjugués immunogéniques multivalents complexes
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
PT2004225E (pt) 2006-03-22 2012-05-30 Novartis Ag Regimes para imunização com conjugados meningocócicos
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
US20100021503A1 (en) * 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
CL2007000839A1 (es) * 2006-03-30 2008-01-25 Glaxosmithline Biolog S A Procedimiento para producir un conjugado que comprende un polisacárido u oligosacárido de tipo 5 u 8 de s. aureus y una proteína portadora; conjugado inmunogénico que lo comprende; vacuna que comprende al conjugado; procedimiento de obtención de dicha vacuna; y uso del conjugado para tratar o prevenir la infección por estafilococos
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2054431B1 (fr) * 2006-06-09 2011-08-31 Novartis AG Conformères d'adhésines bactériennes
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2064230A2 (fr) 2006-08-16 2009-06-03 Novartis AG Immunogènes pour escherichia coli uropathogène
RU2460539C2 (ru) * 2006-10-10 2012-09-10 Вайет СПОСОБ ОЧИСТКИ ПОЛИСАХАРИДОВ Streptococcus pneumoniae 3 ТИПА (ВАРИАНТЫ)
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2687228B1 (fr) * 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccin contenant des conjugues de polysaccharide capsulaire de streptococcus pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
ES2383231T3 (es) 2007-10-19 2012-06-19 Novartis Ag Formulaciones para vacunas meningocócicas
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
DK2235046T3 (da) 2007-12-21 2012-10-29 Novartis Ag Mutante former af streptolysin-O
EP2252326A4 (fr) * 2008-02-01 2012-08-29 Newcastle Innovation Ltd Compositions de vaccin
EP2886551A3 (fr) 2008-02-21 2015-09-23 Novartis AG Polypeptides fHbp méningococciques
WO2009114485A2 (fr) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Protéines chimères de liaison du facteur h contenant un domaine b hétérologue, et procédés d’utilisation associés
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
CN102264444B (zh) 2008-10-27 2015-08-05 诺华股份有限公司 纯化方法
JP5209800B2 (ja) 2008-12-09 2013-06-12 ファイザー バクシーンズ エルエルシー ＩｇＥＣＨ３ペプチドワクチン
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
EP2367568A2 (fr) 2008-12-17 2011-09-28 Novartis AG Vaccins méningococciques comprenant un récepteur de l'hémoglobine
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
CN102481349B (zh) 2009-01-12 2014-10-15 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
CA2756533A1 (fr) 2009-03-24 2010-09-30 Novartis Ag Combinaisons de proteine liant le facteur h de meningocoque et de conjugues de saccharide de pneumocoque
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP2419129A2 (fr) 2009-04-14 2012-02-22 Novartis AG Compositions pour l'immunisation contre staphylococcus aureus
WO2010132833A1 (fr) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Compositions vaccinales contre streptococcus et méthodes d'utilisation associées
WO2011041003A2 (fr) 2009-06-22 2011-04-07 Wyeth Llc Compositions et procédés d'élaboration de compositions immunogènes conjuguées à polysaccharides capsulaires de sérotypes 5 et 8 de staphylococcus aureus
WO2010151544A1 (fr) 2009-06-22 2010-12-29 Wyeth Llc Compositions immunogènes d'antigènes de staphylococcus aureus
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
PE20120817A1 (es) 2009-07-30 2012-07-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
JP2013503623A (ja) * 2009-09-03 2013-02-04 ファイザー バクシーンズ エルエルシー Ｐｃｓｋ９ワクチン
JP2013504556A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 気道疾患に対する組み合わせワクチン
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
RS56000B1 (sr) 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
MX2012006961A (es) 2009-12-17 2012-10-03 Fina Biosolutions Llc Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
CN102762224A (zh) 2009-12-22 2012-10-31 塞尔德克斯医疗公司 疫苗组合物
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN102834410B (zh) 2010-03-30 2016-10-05 奥克兰儿童医院及研究中心 改性的h因子结合蛋白（fhbp）及其使用方法
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2555753B1 (fr) 2010-04-07 2018-08-01 California Institute of Technology Véhicule destiné à distribuer un composé à une muqueuse et compositions, procédés et systèmes apparentés
JP2013530949A (ja) * 2010-05-20 2013-08-01 エル ラウンド ジューン 抗原特異的Ｔｒｅｇ並びに関連する組成物、方法及びシステム
AU2011262346B2 (en) * 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
CA2798837A1 (fr) 2010-06-07 2011-12-15 Pfizer Inc. Peptides her-2 et vaccins
CA2800774A1 (fr) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Vaccin peptidique ige ch3
EP2585106A1 (fr) 2010-06-25 2013-05-01 Novartis AG Associations de protéines de liaison du facteur h méningococcique
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2655389A2 (fr) 2010-12-24 2013-10-30 Novartis AG Composés
WO2012103421A1 (fr) 2011-01-27 2012-08-02 Novartis Ag Nanoémulsions d'adjuvant à inhibiteurs de cristallisation
CA2828844C (fr) 2011-03-02 2020-07-14 Novartis Ag Vaccins combines comprenant des doses inferieures d'antigene et/ou d'adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2688590B1 (fr) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Nanoémulsions adjuvantes avec des phospholipides
EP2511295A1 (fr) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions pour la prévention et/ou le traitement d'une infection par un virus VIH-1
EP2705853B1 (fr) 2011-05-06 2018-07-18 Aparin, Petr Gennadievich Exopolysaccharide de la bactérie shigella sonnei, son procédé de production, vaccin et composition pharmaceutique le contenant
JP6499446B2 (ja) 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
EP2757882B1 (fr) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Composés imidazopyridyliques utilisables en tant qu'inhibiteurs de l'aldostérone synthase
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
EP2592137A1 (fr) 2011-11-11 2013-05-15 Novartis AG Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
ES2704069T3 (es) 2011-12-08 2019-03-14 Glaxosmithkline Biologicals Sa Vacuna basada en toxinas de Clostridium difficile
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
AU2013224026A1 (en) 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013254751B2 (en) 2012-04-26 2017-12-14 Glaxosmithkline Biologicals S.A. Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
WO2013174832A1 (fr) 2012-05-22 2013-11-28 Novartis Ag Conjugué de sérogroupe x de méningocoque
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
CA2896552A1 (fr) 2012-10-03 2014-04-10 Novartis Ag Compositions immunogenes
EP3620172A1 (fr) 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Antigènes de pertussis acellulaires non réticulés pour leur utilisation dans des vaccins combinés
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
EA201590490A1 (ru) * 2012-10-17 2015-10-30 Глаксосмитклайн Байолоджикалс С.А. ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ОДИН ИЛИ БОЛЕЕ КОНЪЮГАТОВ КАПСУЛЬНЫХ САХАРИДОВ STREPTOCOCCUS PNEUMONIAE И БЕЛКОВЫЙ КОМПОНЕНТ, ВКЛЮЧАЮЩИЙ БЕЛОК Е И/ИЛИ PilA ИЗ HAEMOPHILIUS INFLUENZAE
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
EP3689375A1 (fr) 2013-05-15 2020-08-05 The Governors Of The University Of Alberta Vaccins contre le vhc e1e2 et procédés d'utilisation desdits vaccins
CN103386126B (zh) * 2013-06-25 2015-06-17 北京科兴生物制品有限公司 一种含肠道病毒抗原的多价免疫原性组合物
US9822150B2 (en) 2013-09-08 2017-11-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
PE20212335A1 (es) 2014-01-21 2021-12-16 Pfizer Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
EP3104877B1 (fr) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin
CA2940447C (fr) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Polypeptides fhbp meningococciques modifies
EP2921856B1 (fr) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited Analyse quantitative pour de la 4-pyrrolidinopyridine (4-ppy) dans des vaccins conjugués polyssacharide-protéine
CN104829711B (zh) * 2014-04-08 2018-04-03 北京天成新脉生物技术有限公司 脑膜炎球菌荚膜多糖单克隆抗体及其应用
CN106715464B (zh) 2014-07-23 2021-03-16 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (fr) 2014-12-19 2016-06-22 Novartis AG Purification de polysaccharides capsulaires de streptocoques
CN107427568B (zh) 2015-01-15 2021-12-14 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
CN104548090B (zh) * 2015-01-27 2016-11-30 中国科学院过程工程研究所 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
WO2016184963A1 (fr) 2015-05-19 2016-11-24 Innavirvax Traitement de patients souffrant d'une infection par le vih
WO2016201342A1 (fr) 2015-06-10 2016-12-15 California Institute Of Technology Traitement du sepsis, compositions, méthodes et systèmes associés
EP3109255A1 (fr) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Composition immunogène
CA2991544A1 (fr) 2015-07-07 2017-01-12 Affiris Ag Vaccins pour le traitement et la prevention de maladies mediees par ige
TWI720448B (zh) 2015-07-21 2021-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
CA2996383A1 (fr) 2015-08-25 2017-03-02 Nancy GUPTA Compositions d'immunomodulation et leurs procedes d'utilisation
CA3000313A1 (fr) 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Heterodimeres e1/e2 du virus de l'hepatite c et leurs procedes de production
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
US10993971B2 (en) 2015-12-04 2021-05-04 Dana-Farber Cancer Institute, Inc. Vaccination with MICA/B alpha 3 domain for the treatment of cancer
PT3405212T (pt) 2016-01-19 2020-08-25 Pfizer Vacinas para o cancro
WO2017175082A1 (fr) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Compositions immunogènes
EP3474890A1 (fr) * 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Composition de conjugué polysaccharide pneumococcique-protéine
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
PH12019500238B1 (en) 2016-08-05 2023-05-10 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
CA3039322A1 (fr) 2016-10-07 2018-04-12 Enterome S.A. Composes immunogenes pour la cancerotherapie
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
WO2018104889A1 (fr) 2016-12-06 2018-06-14 Glaxosmithkline Biologicals Sa Procédé de purification pour polysaccharide capsulaire
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
WO2018142280A2 (fr) 2017-01-31 2018-08-09 Pfizer Inc. Compositions de neisseria meningitidis et méthodes associées
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110520154B (zh) * 2017-03-15 2023-08-04 株式会社Lg化学 多价肺炎链球菌疫苗组合物
WO2018178264A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et méthode de traitement
WO2018178265A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et procédé de traitement
KR20240018697A (ko) 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US11723966B2 (en) 2017-08-14 2023-08-15 Glaxosmithkline Biologicals Sa Methods of boosting immune responses
EP3691677A4 (fr) 2017-10-04 2021-07-07 Pogona, Llc Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
CA3084436A1 (fr) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprenant des conjugues polysaccharide-proteine de streptococcus pneumoniae et leurs methodes d'utilisation
CA3087572A1 (fr) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Composition de conjugue polysaccharide-proteine pneumococcique multivalent
CN118903402A (zh) 2018-02-05 2024-11-08 赛诺菲巴斯德有限公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
PL3773689T3 (pl) 2018-04-11 2023-03-13 Enterome S.A. Peptydy antygenowe do zapobiegania i leczenia raka
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
JP2021522213A (ja) 2018-04-18 2021-08-30 エスケー バイオサイエンス カンパニー リミテッド ストレプトコッカス・ニューモニエ莢膜多糖類及びその免疫原性接合体
BR112021000529A2 (pt) 2018-07-19 2021-04-06 Glaxosmithkline Biologicals S.A. Processos para preparar polissacarídeos secos
CA3107077A1 (fr) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processus et vaccins
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
JOP20210148A1 (ar) 2018-12-19 2023-01-30 Merck Sharp & Dohme تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
WO2020146814A1 (fr) * 2019-01-11 2020-07-16 Northwestern University Synthèse de vaccins bioconjugués dans des lysats cellulaires procaryotes
CA3129425A1 (fr) 2019-02-11 2020-08-20 Pfizer Inc. Compositions de neisseria meningitidis<i /> et procedes associees
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
BR112021022429A2 (pt) 2019-05-10 2022-03-22 Glaxosmithkline Biologicals Sa Produção de conjugados
BR112021026775A2 (pt) 2019-08-05 2022-05-10 Glaxosmithkline Biologicals Sa Processo para preparar uma composição que compreende um polipeptídeo de proteína d
US20230066762A1 (en) 2019-08-05 2023-03-02 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4034157A1 (fr) 2019-09-27 2022-08-03 Pfizer Inc. Compositions de neisseria meningitidis et méthodes associées
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
AU2020375214B2 (en) 2019-11-01 2024-02-08 Pfizer Inc. Escherichia coli compositions and methods thereof
SI4021487T1 (sl) 2019-11-15 2024-03-29 Enterome S.A., Antigenski peptidi za preprečevanje in zdravljenje b-celične malignosti
CA3161857A1 (fr) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage et administration d'un vaccin a base de glycoconjugue de saccharide bacterien
WO2021138495A1 (fr) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particules pour administration multi-dose
WO2021165847A1 (fr) 2020-02-21 2021-08-26 Pfizer Inc. Purification de saccharides
KR20220143910A (ko) 2020-02-23 2022-10-25 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그의 방법
CN111588847B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种含有单磷酸化的脂质a与糖抗原的缀合物及其制备方法和应用
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
EP4192499A4 (fr) 2020-08-10 2024-09-25 Inventprise, Inc. Vaccins glycoconjugués pneumococciques multivalents contenant un sérotype 24f émergent
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
JP2022075575A (ja) 2020-11-04 2022-05-18 ファイザー・インク 肺炎球菌ワクチンにおける使用のための免疫原性組成物
JP2023549736A (ja) 2020-11-10 2023-11-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
CA3211240A1 (fr) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Vaccin recombinant meningococcique b
US20240148849A1 (en) 2021-02-22 2024-05-09 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4070814A1 (fr) 2021-04-07 2022-10-12 Lama France Polypeptides sars-cov-2 et leurs utilisations
KR20230175284A (ko) 2021-05-28 2023-12-29 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (fr) 2022-01-13 2023-07-20 Pfizer Inc. Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2023161817A1 (fr) 2022-02-25 2023-08-31 Pfizer Inc. Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
WO2023187127A1 (fr) 2022-03-31 2023-10-05 Enterome S.A. Peptides antigéniques pour la prévention et le traitement du cancer
IL316477A (en) 2022-05-11 2024-12-01 Pfizer Process for producing vaccine formulations with preservatives
WO2024110827A1 (fr) 2022-11-21 2024-05-30 Pfizer Inc. Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (fr) 2022-12-01 2024-06-06 Pfizer Inc. Formulations de vaccin pneumococcique conjugué
WO2024166008A1 (fr) 2023-02-10 2024-08-15 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024201324A2 (fr) 2023-03-30 2024-10-03 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées
WO2024214016A1 (fr) 2023-04-14 2024-10-17 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024224266A1 (fr) 2023-04-24 2024-10-31 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU626961B2 (en) * 1988-12-16 1992-08-13 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (fr) * 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
EP0618813B1 (fr) * 1992-09-16 2002-01-09 The University Of Tennessee Research Corporation Antigene de la proteine m hybride et porteur destine au vaccin anti-streptococcique du groupe a
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
ATE226831T1 (de) 1993-05-18 2002-11-15 Univ Ohio State Res Found Impfstoff gegen mittelohrentzündung
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
CA2194761C (fr) 1994-07-15 2006-12-19 Arthur M. Krieg Oligonucleotides immunomodulateurs
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
AU716806B2 (en) * 1995-04-17 2000-03-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
EP0831901B2 (fr) 1995-06-07 2005-12-07 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccins comprenant un conjugue antigene de polysaccharide-proteine porteuse et une proteine porteuse libre
PL323781A1 (en) 1995-06-07 1998-04-27 Biochem Vaccines Inc Streptococco thermal shock proteins belonging to a family hsp70
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
EP0912608B1 (fr) 1996-05-01 2006-04-19 The Rockefeller University Proteines fixant la choline pour vaccins anti-pneumococciiques
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk グレーチング
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
ATE380867T1 (de) 1997-06-03 2007-12-15 Sanofi Pasteur Ltd Lactoferrinrezeptorgen von moraxella
CA2297374A1 (fr) 1997-07-21 1999-01-28 North American Vaccine, Inc. Compositions de pneumolysine immunogene modifiee utiles en tant que vaccins
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
HUP0102617A3 (en) 1998-04-07 2006-04-28 Medimmune Inc Gaithersburg Derivatives of pneumococcal choline binding proteins for vaccines
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
KR100704826B1 (ko) 1998-08-19 2007-04-09 박스터 헬쓰케어 에스.에이. Ｎ-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트
DK1140157T3 (da) * 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner
SI1163000T1 (sl) 1999-03-19 2008-06-30 Glaxosmithkline Biolog Sa Vakcina proti antigenom iz bakterij
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 富士康(昆山)电脑接插件有限公司 线缆连接器组件

Also Published As

Publication number Publication date
BR0009163A (pt) 2001-12-26
NO20014325D0 (no) 2001-09-05
TR200102736T2 (tr) 2002-04-22
TR200102735T2 (tr) 2002-04-22
CY2009014I1 (el) 2010-07-28
DE122009000054I1 (de) 2009-12-31
PL355178A1 (en) 2004-04-05
CA2366314C (fr) 2012-01-10
NZ513840A (en) 2004-02-27
PT1162999E (pt) 2007-02-28
CA2366314A1 (fr) 2000-09-28
NO20014323D0 (no) 2001-09-05
WO2000056359A3 (fr) 2001-02-01
DK1163000T3 (da) 2008-04-28
PL203917B1 (pl) 2009-11-30
ATE459373T1 (de) 2010-03-15
EP2277535A3 (fr) 2011-03-09
SI1163000T1 (sl) 2008-06-30
NO20014325L (no) 2001-11-14
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
KR100642044B1 (ko) 2006-11-10
JP2002540075A (ja) 2002-11-26
CY1107390T1 (el) 2010-07-28
WO2000056358A2 (fr) 2000-09-28
WO2000056359A2 (fr) 2000-09-28
KR20020001785A (ko) 2002-01-09
PL355264A1 (en) 2004-04-05
HK1043728A1 (en) 2002-09-27
LU91652I2 (fr) 2010-10-13
HK1043730A1 (zh) 2002-09-27
JP2002540074A (ja) 2002-11-26
EP1162998B1 (fr) 2010-03-03
WO2000056360A2 (fr) 2000-09-28
ES2339737T3 (es) 2010-05-25
NO2011014I1 (no) 2011-09-19
CN1351501A (zh) 2002-05-29
AR022965A1 (es) 2002-09-04
CN1391481A (zh) 2003-01-15
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
AU3291900A (en) 2000-10-09
NO20014322L (no) 2001-11-14
CZ301445B6 (cs) 2010-03-03
HK1043728B (zh) 2007-06-22
NZ513841A (en) 2001-09-28
TWI235064B (en) 2005-07-01
MY125387A (en) 2006-07-31
KR20020000549A (ko) 2002-01-05
EP1880735A2 (fr) 2008-01-23
KR100798212B1 (ko) 2008-01-24
PL204890B1 (pl) 2010-02-26
US20060002961A1 (en) 2006-01-05
MY125202A (en) 2006-07-31
US8926985B2 (en) 2015-01-06
WO2000056360A3 (fr) 2001-01-25
HUP0200664A2 (en) 2002-06-29
JP4846906B2 (ja) 2011-12-28
HK1043731A1 (en) 2002-09-27
EP2277535A2 (fr) 2011-01-26
CA2366152A1 (fr) 2000-09-28
CN100339130C (zh) 2007-09-26
AU750913B2 (en) 2002-08-01
NL300415I1 (nl) 2009-12-01
IL145043A (en) 2007-06-17
CZ303653B6 (cs) 2013-01-30
SI1162999T1 (sl) 2007-04-30
US9168313B2 (en) 2015-10-27
EP1163000B1 (fr) 2008-02-27
BR0009154A (pt) 2001-12-26
ES2300255T3 (es) 2008-06-16
EP1163000A2 (fr) 2001-12-19
PL355180A1 (en) 2004-04-05
EP1162999A2 (fr) 2001-12-19
CY2009014I2 (el) 2010-07-28
TWI286938B (en) 2007-09-21
CN1351503A (zh) 2002-05-29
BRPI0009163B1 (pt) 2019-04-09
US20030147922A1 (en) 2003-08-07
FR10C0008I2 (fr) 2012-10-26
DE60032120D1 (de) 2007-01-11
NZ513842A (en) 2004-05-28
HU228499B1 (en) 2013-03-28
DE60032120T2 (de) 2007-09-20
EP1162999B1 (fr) 2006-11-29
US20060093626A1 (en) 2006-05-04
BRPI0009163B8 (pt) 2021-05-25
MXPA01009452A (es) 2002-08-06
EP1776962A1 (fr) 2007-04-25
KR20020000785A (ko) 2002-01-05
IL145045A0 (en) 2002-06-30
LU91652I9 (fr) 2019-01-03
TWI281403B (en) 2007-05-21
EP1880735A3 (fr) 2008-03-12
NO330736B1 (no) 2011-06-27
AU750762B2 (en) 2002-07-25
NO20014322D0 (no) 2001-09-05
AR022964A1 (es) 2002-09-04
AU3813600A (en) 2000-10-09
DE60038166T2 (de) 2009-03-12
AU3430700A (en) 2000-10-09
CN1192798C (zh) 2005-03-16
IL145044A0 (en) 2002-06-30
JP5551579B2 (ja) 2014-07-16
HU229968B1 (hu) 2015-03-30
CZ20013378A3 (cs) 2002-03-13
FR10C0008I1 (fr) 2010-03-26
AR022963A1 (es) 2002-09-04
JP2002539273A (ja) 2002-11-19
TR200102739T2 (tr) 2001-12-21
CN1191852C (zh) 2005-03-09
NO2011014I2 (no) 2011-08-30
BR0009166A (pt) 2001-12-26
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
US20100119544A1 (en) 2010-05-13
AU750788B2 (en) 2002-07-25
NO330532B1 (no) 2011-05-09
ATE387214T1 (de) 2008-03-15
HUP0200373A2 (en) 2002-06-29
US20110217329A1 (en) 2011-09-08
IL145044A (en) 2007-03-08
IL145043A0 (en) 2002-06-30
CZ20013379A3 (cs) 2002-03-13
DE60038166D1 (de) 2008-04-10
HUS1500040I1 (hu) 2018-05-28
NL300415I2 (fr) 2016-12-13
HK1043731B (zh) 2009-01-23
US20050031646A1 (en) 2005-02-10
BE1025464I2 (fr) 2019-03-06
HUP0200367A2 (en) 2002-05-29
JP2011057713A (ja) 2011-03-24
DE60043930D1 (de) 2010-04-15
EP1162998A2 (fr) 2001-12-19
CA2365296A1 (fr) 2000-09-28
WO2000056358A3 (fr) 2001-01-04
ATE346608T1 (de) 2006-12-15
CY1107561T1 (el) 2013-03-13

Similar Documents

Publication Publication Date Title
DK1162999T3 (da) Vaccine imod Streptococcus pneumoniae
NO20043018L (no) Streptococcus pneumoniae vaksine
NO20021433L (no) Vaksiner
ATE335404T1 (de) Kaubares konfektprodukt
DE50115224D1 (de) Verriegelungsnagel
EP1083926A4 (fr) Vaccin
DK1139764T3 (da) Adjuvanssammensætning
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20020763L (no) Vaksine
ATE272046T1 (de) O-substituierte 6-methyl-tramadol-derivate
NO20005599L (no) Vaksine
DE60012038D1 (de) Nicht-fettiges abschminkmittel
NO20005141D0 (no) Streptokokkpreparat
EP1147118A4 (fr) Disaccharides a liaison alpha non substitues
SE9602149D0 (sv) Conjugate vaccine against streptococcus pneumoniae
ATA74199A (de) Kryosonde
ES1043924Y (es) Sobre
FI19992346L (fi) TETRA-järjestelmä
IT246821Y1 (it) Cuscino
FIU990408U0 (fi) Tyyny
FR2797263B1 (fr) Oligonucleotide immunostimulant
AU2001282771A1 (en) Coulomb blockade thermometer
ITMI990086A1 (it) Pinza spingibarra
UA3210S (uk) Профіль
UA3211S (uk) Профіль
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载